培美曲塞加顺铂化疗联合热疗治疗进展期肺腺癌

Chemotherapy with pemetrexed plus cisplatin and hyperthermia in the treatment of advanced lung adencarcinoma

目的 评价培美曲塞加顺铂化疗联合热疗对进展期肺腺癌的近期疗效和不良反应.方法 经病理组织学或细胞学证实的中晚期肺腺癌39例患者,采用培美曲塞、顺铂全身化疗,培美曲塞500 mg/m^2静脉滴注,第1天;顺铂60 mg/m^2分第1～3天给药,同时配合内生场热疗,2次/周,21 d为1周期.结果 39例患者中无CR,PR 21例（53.85％）,SD 12例（30.77％）,PD 6例（15.38％）,疾病缓解率（CR＋PR）为53.85％,疾病控制率（CR＋PR＋SD）为84.62％.不良反应主要为骨髓抑制、胃肠道反应等,大部分为Ⅰ、Ⅱ度,患者耐受良好.结论 培美曲塞加顺铂化疗联合内生场热疗是一种对中晚期肺腺癌安全有效的治疗方案.

Objective To evaluate the efficacy and toxicity of chemotherapy with pemetrexed plus cisplatin and endogenetic field hyperthermia in the treatment of advanced lung adencarcinoma. Methods Thirty nine patients with locally advanced or metastatic lung adencarcinoma were enrolled into this study. The patients received pemetrexed 500mg/m2 on day 1,cisplatin 60mg/m2 average on day 1 to day 3 and NRL-001 endogenetic field hyperthermia twice every week,21 days were a treatment cycle. Results Among the 39 patients,partial remission was in 21 patients（53.85%）,stable disease in 12 patients （30.77% ） ,progressive disease in 6 patients（15.38）. The total response rate was 53.85% and clinical benefit control rate was 84.62%. The most common adverse reaction was myelosuppression and gastrointestinal reaction. All of patients tolerated the treatment better only with adverse reaction of I or II degree. Conclusion Pemetrexed combined with cisplatin for chemotherapy and endogenetic field hvoerthermia is an effective and well tolerated treatment plan.